Talk to an Scientist
Talk to an Scientist

Product

GOLDILOCKS™
stable CHO-K1 Kit

Pool predicts clone. Every molecule. Every time.

  • 7-14 g/L clone titers
  • >95% stability at 60 gen
  • 100-200 kb cargo capacity
  • 4-chain co-integration

Core bottlenecks

Why cell line development still stalls — and what GOLDILOCKS removes from the process

Traditional workflows still rely on workarounds: random integration can be unstable, codon optimization is inconsistent, and multichain molecules often require extra rounds of signal peptide and vector screening.

Even improved transposase approaches leave failure modes in place, adding cost and stretching timelines.

  1. Random Integration

    • What happens with traditional CLD
    • Cassette rearrangements; regulatory elements drift from ORFs
    • Concatemer formation drives repeat-induced silencing
    • Integration sites unpredictable – many silenced
    • Pool titer doesn’t predict clone titer

  2. Standard Transposase Platforms

  3. The Optimization Gauntlet

How GOLDILOCKS Works

  • Co-Transfection

    • Transposase mRNA + pGL™ vector
    • Optimized HTP transfection into SUPERCELL™
    • Single vector design for all molecules
    Scroll

  • Multi-Site Integration

    • Inserts intact cassette at 15-20 loci
    • Single copy per site – no concatemers
    • Biased toward active chromatin
    Scroll

  • Stable Expression

    • Pool titers >14 g/L
    • 50% increase from pool to clone
    • No selection pressure required
    • Stable >120 generations
    Scroll

Key advantages

GOLDILOCKS™ is the only transposase platform engineered to eliminate every failure mode of random integration at the source – not to work around them.

  • Single-copy, multi-site integration

    15-20 independent integration sites, one copy per site. Eliminates the concatemer-induced silencing that drives expression decline in random-integration cell lines.

  • Intact cassette architecture

    The entire expression cassette integrates as a single unit – regulatory elements stay linked to their ORFs. No rearrangements, no orphaned promoters, no broken stoichiometry.

  • Active-chromatin targeting

    Integration is biased toward transcriptionally active loci. Your gene lands where the cell is already willing to express – not in heterochromatic silencing zones.

  • Pool predicts clone

    Clones average 50% above pool titer with tight distribution. Screen fewer clones.

  • Universal vector – every modality

    Universal pLG™ construct handles mAbs, bispecifics, ADCs, Fc-fusions, nanobody fusions, enzymes, cytokines. No per-molecule optimization. Up to 100-200 kb cargo.

  • Built-in genetic stability

    >95% expression retained over 120+ generations without selective pressure.

Proof points

GOLDILOCKS data — titers,
predictability, stability

Stable pool titers across 6 representative programs:
Fc-fusion, nanobody fusion, 4-chain bispecific, lipoprotein, and two mAbs. All ≥7 g/L.

Pool titers reliably predict clone performance, reducing the number of clones that need to be screened.

Expression remains stable through extended culture without ongoing selection pressure.

How to Access GOLDILOCKS

GOLDILOCKS™ options — start with Pool Evaluation, then choose path

  • Pool evaluation

    Prove GOLDILOCKS first

    Test the platform before committing to a path:

    • 5-week stable pool + fed-batch COA
    • Accessible entry-point pricing
    • Pool preserved at Celltheon
    • Same path for Kit or Service

    Ideal for: platform evaluation, early biology readouts, molecule de-risking.

    Talk to a Scientist
  • License the kit

    Run GOLDILOCKS in your own lab

    For groups with in-house CLD infrastructure

    • Transposase mRNA + pGL™ vector
    • SUPERCELL™ CHO-K1 host
    • ELIXIR™ media + feed protocols
    • SOPs, training, and tech support

    Ideal for: labs running 5+ CLD programs/year, platform CDMOs, scaled biotech R&D.

    Talk to a Scientist
  • Full-service CLD

    We run GOLDILOCKS for you

    For groups with in-house CLD infrastructure

    • Transposase mRNA + pGL™ vector
    • SUPERCELL™ CHO-K1 host
    • ELIXIR™ media + feed protocols
    • SOPs, training, and tech support

    Ideal for: most biotech programs; gene to clone with no in-house CLD burden.

    Talk to a Scientist
Frequently asked questions

Quick answers
to common questions

Quick answers about timelines, quality, and how to work with Celltheon.

Celltheon builds biotech technology platforms and delivers end-to-end solutions that bridge early drug development and manufacturing.

We support biotech and biopharma teams from discovery through preclinical development and manufacturing readiness.

Our offering spans DNA, protein production, engineering, developability, assays, stable cell lines, conjugation, and process development.

Both. Programs can use an integrated workflow or select the individual services and technologies they need.

Yes. Choose platform transfer to your team or a service model executed by Celltheon scientists.

We begin with your goals, molecule, timeline, and deliverables, then provide a clear technical plan and project scope.

We share relevant case studies, quality documentation, platform data, and a project-specific package aligned with your requirements.

Discuss your molecule with our scientists

We don’t workaround — we innovate
and deliver

Explore whether OmniCHO™ is the right expression platform for your specific protein format.

Talk to a Scientist